NCT07088679 Natural Bioactive Gel for Peri-Implantitis
| NCT ID | NCT07088679 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pavia |
| Condition | Peri-implantitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-07-30 |
| Primary Completion | 2026-05-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2025-07-30 with a primary completion date of 2026-05-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a randomized controlled clinical trial using a split-mouth design to evaluate the effectiveness of a natural bioactive gel (Sterify Gel®) as an adjunct to standard non-surgical therapy for peri-implantitis. Peri-implantitis is an inflammatory disease that affects the tissues around dental implants and can lead to bone loss and implant failure. The goal of the study is to determine whether the application of Sterify Gel®, which contains polyvinyl polymers, hydroxytyrosol, magnesium ascorbyl phosphate, and nisin, can improve clinical outcomes when used in addition to conventional mechanical debridement and air-polishing. The trial will include 20 patients, each with at least two implants in different quadrants affected by peri-implantitis. One implant will be treated with standard therapy plus the gel (test site), while the other will receive standard therapy alone (control site). Clinical outcomes will be measured over a 9-month period, including plaque levels, bleeding on probing, probing depth, suppuration, and bone loss. The results will help assess whether this gel enhances the effectiveness of routine non-surgical peri-implantitis treatment.
Eligibility Criteria
Inclusion Criteria: * Patients aged between 18 and 70 years * Presence of peri-implantitis involving at least two dental implants located in different quadrants * Presence of bleeding and/or suppuration on probing * Increased probing depth (PD) and radiographic bone loss compared to previous examinations * In the absence of previous clinical data: PD ≥ 6 mm and bone loss ≥ 3 mm apically from the coronal portion of the intraosseous implant area (radiographically assessed) * Willingness and ability to comply with study protocol and follow-up visits * Written informed consent provided Exclusion Criteria: * Patients with cardiac pacemakers or other implanted electronic devices * Neurological or psychiatric disorders that may interfere with study participation * Systemic diseases, metabolic disorders, or autoimmune conditions * Pregnancy or lactation Current participation in other clinical trials
Contact & Investigator
Andrea Scribante, Associate Professor
PRINCIPAL INVESTIGATOR
University of Pavia
Frequently Asked Questions
Who can join the NCT07088679 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Peri-implantitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07088679 currently recruiting?
Yes, NCT07088679 is actively recruiting participants. Contact the research team at andrea.scribante@unipv.it for enrollment information.
Where is the NCT07088679 trial being conducted?
This trial is being conducted at Pavia, Italy.
Who is sponsoring the NCT07088679 clinical trial?
NCT07088679 is sponsored by University of Pavia. The principal investigator is Andrea Scribante, Associate Professor at University of Pavia. The trial plans to enroll 20 participants.